Biofilms are microbial aggregates that consist of bacterial cells and a self-produced matrix 44 primarily composed of proteins, lipids, polysaccharides and nucleic acids [1] . The biofilm 45 matrix provides the microbial population with increased antibiotic tolerance and protection 46 against the host immune response [2] . The persistent, biofilm-associated lung infections that 47 6 This is consistent with the presence of the transposon (994 bp); the expected fragment in the 121 absence of a transposon is ~500 bp. 122 123 Table 1 -Description of the Pseudomonas aeruginosa PA14 transposon insertion mutants used for our work 124 [34, 35] . Information for each gene is provided and the associated CF infection phenotype following loss of gene 125 function [23, 36, 37] was assessed by briefly shaking the well plate then reading absorbance at 600 nm using a Tecan 139 Spark 10M plate reader. Biofilm formation on pegs was quantified using a crystal violet assay 140 [38] . Briefly, pegs were rinsed with 150 µl phosphate-buffered saline (PBS) in a fresh 96-well 141 plate to remove loosely-adhering cells. The peg lid was then transferred to a further 96-well 142 plate with 150 µl 0.1% (w/v) crystal violet (Vickers Laboratories) per well. It was incubated at 143 room temperature for 15 min and the pegs rinsed twice in PBS as above, before drying in a 144 laminar flow hood for 30 min. The pegs were transferred to another 96-well plate containing 145 150 µl 95% (v/v) ethanol per well to solubilise the crystal violet. Absorbance of the solubilised 146 crystal violet was read at 590 nm in a Tecan Spark 10M. The relative allocation of bacterial 147 cells to the biofilm per well was calculated by dividing A590nm of crystal violet by A600nm of 148 corresponding planktonic subpopulation. 149 150 Microscopy of P. aeruginosa grown in vitro in ASM. Three replicate 100 µl aliquots of 151 ASM1 or ASM2, ± 3 µM glucose, per growth condition were inoculated with colonies of PA14, 152 SED42 or SED43 taken from LB agar plates grown overnight at 37 °C. Cultures were incubated 153 at 37 °C for 36 h. Aliquots were taken of each culture, diluted 1:100 in PBS and 10 µl heat 154 fixed on a glass slide. Each fixed, diluted culture was then Gram stained. The stained slides 155 were imaged using a Zeiss Axio Scope.A1 light microscope with the Zeiss Axiocam Erc 5s 156 and Zeiss Zen 2.3 pro software. 157
158
In vitro growth of P. aeruginosa metabolic mutants. Cultures were grown for 6 h in LB at 159 37 °C. Bacterial cells were washed and starved in PBS for 2 h, then resuspended in ASM1 or 160 ASM2. One set of ASM cultures were left as per the original method, and the other 161 supplemented with either 20 µg ml -1 leucine, 20 µg ml -1 methionine or 30 µg ml -1 each of 162 guanine, adenine, xanthine and hypoxanthine as relevant for each mutant. Purines had to be 163 dissolved in NaOH, so the comparative original ASM was supplemented with an equivalent 164 amount of NaOH. Subsequently, 150 µl of each resuspended culture was transferred to a 96-165 well plate and grown for a further 24 h at 37 °C in a Tecan Spark 10M. Every 20 min, the plate 166 was shaken for 5 s and the absorbance read at 600 nm. 167 168 EVPL dissection and infection. EVPL was prepared as previously described [30] . Briefly, 169 porcine lungs were obtained from a local butcher (Quigley and Sons, Cubbington) and 170 dissected on the day of delivery under sterile conditions. The pleura of the ventral surface was 171 heat sterilised using a hot pallet knife. A sterile razor blade was then used to make an incision 172 in the lung, exposing the bronchiole. A section of the bronchiole was extracted and the exterior 173 alveolar tissue removed using dissection scissors. Bronchiolar sections were washed once in a 174 1:1 mix of Dulbecco's modified Eagle medium (DMEM) and RPMI 1640 supplemented with 175 50 µg ml -1 ampicillin (Sigma-Aldrich) then cut into ~5 mm wide longitudinal strips. The 176 bronchiolar strips were placed in a second 1:1 DMEM, RPMI 1640 + 50 µg ml -1 ampicillin 177 wash and cut into squares (~5 x 5 mm). The tissue squares were washed for a third time in 1:1 178 DMEM, RPMI 1640 + 50 µg ml -1 ampicillin. Bronchiolar pieces were then further washed in 179 ASM, UV sterilised for 5 min and transferred to individual wells of a 24-well plate containing 180 400 µl ASM (+ 20 µg ml -1 ampicillin) solidified with 0.8% (w/v) agarose per well. 181 182 A sterile 29G hypodermic needle (Becton Dickinson Medical) was touched to the surface of a 183 P. aeruginosa colony grown on LB agar overnight at 37 °C and used to pierce an individual 184 piece of bronchiolar tissue. Uninfected control tissue sections were mock inoculated with a 185 fresh, sterile needle. Following infection of all tissue pieces, 500 µl of ASM + 20 µg ml -1 186 ampicillin was added to each well. Tissue was incubated at 37 °C with a Breathe-Easier ® 187 membrane (Diversified Biotech) for the desired length of time. was incubated with 170 rpm shaking for 2 h at 37 °C, then stopped by the addition of 100 µl 212 10 120 mM EDTA. The mixture was centrifuged at 13,000 rpm for 1 min and the absorbance of 213 the supernatant read at 400 nm. 214
215
The amount of two quorum sensing (QS) signals in the diluted sterile homogenate was assayed 216
using Escherichia coli biosensors [41] . Expression of a luxCDABE reporter in response to 217 either 3-oxo-C12-HSL or C4-HSL was measured as relative light units (RLU) for E. coli strains 218 carrying the reporter plasmids pSB1075 or pSB406 respectively. represent the presence of host mucins, bacterial membrane and wall components, and the 289 extracellular DNA (eDNA) found in the biofilm plugs formed in the bronchioles of people with 290 CF. ASM2 has been shown to result in a comparable essential genome for P. aeruginosa PA14 291 to lyophilised patient sputum media in vitro [23] . We aimed to determine whether the EVPL 292 model required the more complex ASM2, or whether EVPL + ASM1 would provide a 293 sufficient platform for laboratory growth of P. aeruginosa with more clinically realistic 294 characteristics. 295
296
In our previous work with EVPL, we removed glucose from the original ASM1 formulation as 297 it appeared to enhance the growth of endogenous bacteria from the porcine lungs [31]. We have 298 tested the effects of glucose removal from both versions of ASM on P. aeruginosa growth and 299 biofilm formation in vitro ( Figure S1 ). Our results show small and inconsistent effects of ASM 300 version and glucose removal on PA14 and two clinical CF isolates. The limited effect of 301 glucose removal is consistent with the expectation that P. aeruginosa growth in the CF lung 302 environment mostly depends on using amino acids and short-chain fatty acids as carbon 303 sources [22, 23, 48, 49] . Hence ASM without glucose is the optimal approach for use with EVPL, 304 so glucose was omitted from ASM for all further work. 305
306
When grown for 36 h in vitro, P. aeruginosa appeared to form biofilm-like aggregates in ASM2 307 that were not observed in ASM1, where bacterial cells appeared stressed ( Figure S2 ). However 308 our previous work showed morphologically 'normal' P. aeruginosa growing as extensive 309 biofilms on EVPL + ASM1 4 d PI [30]. This suggests the presence of EVPL overcomes these 310 differences in biofilm formation; therefore, we investigated the effect of ASM version on 311 growth and virulence in EVPL. P. aeruginosa PA14 and clinical isolates SED42 and SED43 312 were used to infect EVPL with either ASM1 or ASM2, and biofilm was recovered 2 d post-313 infection (PI). The biofilm load did not differ between EVPL + ASM1 and EVPL + ASM2 for 314 PA14 or the exemplar clinical isolates ( Figure 1A ). To confirm that ASM version did not 315 impact on other aspects of P. aeruginosa biology, we measured the production of a selection 316 of exoproducts associated with virulence: the quorum sensing signals C4-HSL and 3-oxo-C12 317 HSL, total protease and the siderophores pyoverdine and pyochelin ( Figure 1B ). ANOVAs 318 confirmed that there was not a significant effect of ASM version on any of these variables, as 319 either a main effect or interaction with strain (Table 2) . Principal component analysis did not 320 reveal any clear clustering of phenotypes by ASM version ( Figure S3 ). We also found that 321 EVPL + ASM1 was able to maintain extended P. aeruginosa growth over 14 d ( Figure S4 we compared one key aspect of primary metabolism in EVPL + ASM1 and EVPL + ASM2. 348
Purine biosynthesis was selected as it was previously found to be essential in ASM2 in vitro 349 but not in sputum taken from people with CF [23]. This lack of consistency with true infection 350 highlights a specific area where the composition of ASM2 appears sub-optimal as a model for 351
CF. 352 353
To confirm this previous finding, we performed in vitro growth curves in ASM1 and ASM2 of 354 the laboratory strain wild type (WT) P. aeruginosa PA14 and a PA14 transposon insertion 355 mutant for the purine auxotroph gene purD. We also measured growth of two isogenic mutants 356 auxotrophic for amino acids abundant in ASM: leuB and metX, as positive controls. We found 357 that in both versions of ASM purine supplementation is required for purD mutant growth in 358 vitro (Figure 2A ). 359
360
To identify whether the presence of EVPL could compensate for this shortcoming we infected 361 two independent lungs with the four P. aeruginosa PA14 strains used in vitro (WT; purD, leuB 362 and metX mutants). Bacterial growth was recovered at 2 d PI to determine CFU per lung (Figure  363 2B). This was repeated using either ASM1 or ASM2 with the EVPL. Figure 2B highlights the 364 consistency in CFU per lung of the WT between EVPL + ASM1 and EVPL + ASM2. Statistical 365 analysis found no significant difference in CFU between any individual mutant and the WT in 366 the same version of ASM ( Figure 2B ). Crucially, the purD mutant demonstrated no reduction 367 in bacterial load compared with the WT in the corresponding ASM version. It can be concluded 368 that addition of EVPL removes the essentiality of purine biosynthesis in ASM1, making it 369 consistent with clinical infection. It is also worth noting that the slight growth defect of the WT 370 observed in ASM1 in vitro compared to ASM2 (Figure 2A) is not observable when EVPL is 371 added ( Figure 2B ). 372
373
In conclusion, there does not appear to be any significant differences in P. aeruginosa growth, 374 virulence or purine metabolism in EVPL + ASM1 and EVPL + ASM2. We therefore used 375 EVPL + ASM1 to explore the architecture of P. aeruginosa biofilms formed. 376 (ANOVA: F3,38 = 0.56, p = 0.448 and F1,38 = 0.46, p = 0.712). Biofilm load was affected by the version 391 of ASM used (main effect F1,38 = 12.1, p = 0.001; interaction with genotype F3,38 = 3.50, p = 0.024). A 392 Tukey test showed statistical interaction was driven by the purD mutant (p < 0.01). Planned contrasts by 393 conducting t-tests where t = (mutant CFU -WT CFU in the same medium)/SEdiff, where SEdiff is the 394 standard error of the difference, calculated using the residual mean square from the ANOVA, showed no 395 significant difference in CFU between individual mutants and WT in the same version of ASM (2-tailed 396 p ≥ 0.126). Biofilm formation is arguably the defining phenotype of chronic P. aeruginosa lung infection 401 in individuals with CF. Following identification of optimal EVPL model conditions, we 402 explored the structure and mechanisms of biofilm formation by P. aeruginosa PA14 on EVPL 403 + ASM1. We compared the biofilm formed by WT PA14 with those formed by transposon 404 insertion mutants for the genes gacA and pelA. Both gacA and pelA are important in biofilm 405 infection by P. aeruginosa PA14; either by direct regulation (gacA) or production of a 406 structural matrix polysaccharide (pelA). GacA is a response regulator from the global activator 407 of antibiotic and cyanide synthesis (Gac) two-component regulatory system. The Gac system 408 is well-studied and known to be largely responsible for the switch from acute to chronic 409 infection; in particular it regulates biofilm maturation [50,51]. PelA is a periplasmic protein 410 required for biosynthesis of the biofilm matrix exopolysaccharide Pel. It is one of three 411 exopolysaccharides associated with P. aeruginosa biofilm formation: Pel, Psl and alginate. In 412 PA14, alginate is non-essential for biofilm formation and PA14 is Psl deficient. Hence, biofilm 413 formation in this strain requires the Pel exopolysaccharide [52] . 414 415 20
To measure and visualise the biofilm formed by P. aeruginosa PA14 WT and the gacA and 416 pelA mutants, strains were inoculated individually into replica lung pieces from three 417 independent lungs. Uninfected tissue was used as the negative control. We recovered the 418 biofilm at 2 d and 7 d PI to determine CFU per EVPL section across an extended time period 419 ( Figure 3A ). ANOVAs identified a significant difference in CFU per EVPL tissue section 420 between both the gacA and pelA mutants and the WT at 2 d PI ( Figure 3A ). However, there 421 was only a significant difference in CFU per EVPL section between the gacA mutant and WT 422 7 d PI ( Figure 3A) . The interaction term between replicate lungs and infection strain was found 423 to be significant, reflecting the natural variation between lungs. This is not dissimilar to the 424 patient-to-patient variation expected clinically. 425 426 21 interaction F8,60 = 1.99, P = 0.06). Post-hoc analysis showed that there was significantly higher CFU 433 22 recovered of the gacA mutant compared to the WT (P < 0.01), and higher CFU of pelA mutant than the 434 WT (P = 0.01). At 7 d PI a significant difference in bacterial recovery was found between strains and 435 between lungs, as well as a significant interaction between strain and lung (ANOVA: strain F4,60 = 436 5.40, P < 0.01; lung F2,60 = 78.98, P < 0.01; interaction F8,60 = 2.01, P = 0.06). There was no longer a 437 significant difference in CFU per lung between the WT and pelA mutant (P = 0.69). A significantly 438 greater CFU per lung was recovered from the gacA mutant than the WT (P = 0.047) 7 d PI. (B)
439
Micrograph of Gram-stained PA14 WT and selected transposon mutants in EVPL + ASM1 at 2 d and 7 440 d PI. All images are at x100 magnification.
442
We found that the standard crystal violet biofilm assay was not suitable for use on ex vivo tissue 443 samples. As shown in Figure S6 Figure 3B ). The Gram stain images also 454 demonstrate the increase in density of bacterial cells from 2 d PI to 7 d PI for both mutants and 455 the WT. Bacterial cells do not appear obviously stressed, maintaining their typical rod shape, 456 in contrast with observations of P. aeruginosa grown in ASM1 in vitro ( Figure S2) . 457
458
H & E staining was also performed on replica sections from two independent lungs, and 459 exemplar images for each strain at 7 d PI are shown in Figure 4 (replicate images from second 460 lung: Figure S7 ). Although biofilm formation was detectable 2 d PI based on previously 461 reported biofilm H & E staining [53, 54] , the structure was not as defined ( Figure S8) . At both 462 time-points the WT had formed a biofilm on the surface of the tissue. By 7 d PI, WT PA14 463 appeared to have formed a mature, structured biofilm ( Figure 4A ). We were also able to image 464 individual WT cells stained with H & E. This showed their density and association with EVPL 465 tissue 7 d PI, as well as a distinct lack of obvious stress over the prolonged infection period 466 ( Figure 4B ). 467 468 There were consistent differences in the biofilm observed between the mutant strains and WT 469 7 d PI using H & E staining. This was also evident in the biofilm depth measurements taken 470 from the images (Figure S9 ). At 7 d PI we observed a clear difference in the biofilm formed by 471 the WT and gacA mutant ( Figure 4A ). The mature structure of the WT biofilm was not present 472 in the biofilm formed by the gacA mutant: the purple stained region on the surface of the EVPL 473 tissue demonstrates the homogenous, dense biofilm formed by the gacA mutant ( Figure 4A ). 474
The pelA mutant exhibited greater observable differences in biofilm formation from the WT at 475 both 2 d and 7 d PI ( Figure S7 ; Figure 4B ; Figure S9 ). Our images of the pelA mutant biofilm 476 are comparable to the negative control uninfected tissue, despite presence of mutant infection 477 found by Gram staining and CFU counts (Figure 3) . We identified only a thin layer of purple 478 stain at 7 d PI ( Figure 4B ). Although the pelA mutant was able to grow on EVPL tissue, it was 479 unable to form a biofilm. 480 481 24
Our findings confirm that P. aeruginosa PA14 is able to form mature, highly structured biofilm 482 communities on the surface of EVPL + ASM1. As expected for a chronic biofilm infection, 483 both the Gac regulatory system and the Pel polysaccharide are required for this outcome. 484 485 25 there is a growing medical and economic need for novel and improved treatments for lung 505 infections that are more effective and less rigorous. The rising incidence of antimicrobial 506 resistance (AMR) is only adding to this pressure. Prescribing cannot be improved, nor can a 507 true insight into the impact of potential novel treatment agents (e.g. anti-virulence drugs) be 508 achieved, until there is a better understanding of the fundamental microbiology underpinning 509 these chronic biofilm infections. We aimed to develop a clinically-relevant ex vivo model for 510 the predominant cause of chronic CF lung infections: P. aeruginosa. We have demonstrated 511 that addition of EVPL tissue to a simple formulation of ASM results in a clinically realistic P. 512 aeruginosa biofilm, overcoming a number of obstacles associated with current laboratory 513 models of CF infection. 514 27 515
We initially aimed to define the optimal P. aeruginosa culture conditions for the EVPL model 516 to ensure we are closely modelling clinical CF lung infections. Investigation of P. aeruginosa 517 growth, virulence and purine biosynthesis showed that addition of the porcine bronchiolar 518 tissue overcomes issues associated with in vitro growth in the laboratory media ASM1 and 519 ASM2. 520 521 ASM1 is simpler and cheaper to make than ASM2, thus our conclusion that ASM1 is 522 sufficiently realistic when used with EVPL makes the system readily accessible and tractable 523 for use in research and potentially diagnostic laboratories. It is plausible that ASM1 is sufficient 524 with the addition of EVPL for two primary reasons. Firstly, mucin is unlikely to be an important 525 physiological cue in vivo and in EVPL as it is a poorly used carbon source for P. aeruginosa 526 [49, 56] . In vitro it is likely that mucin acts as a structural cue for P. aeruginosa aggregation 527 and the switch to biofilm lifestyle, however we observed biofilm formation on EVPL in the 528 absence of exogenous mucin. Additionally, the prolonged growth periods and high biofilm 529
densities possible with EVPL mean it is likely that membrane lipids, NAG and eDNA will be 530 released from cells within the tissue and/or maturing biofilm. Our findings suggest that EVPL 531 tissue with ASM1 provides key compounds that are lacking from the media alone, creating a 532 closer match with authentic sputum from CF patients. 533 534 Visualisation of the biofilm is key to comparing laboratory models with in vivo biofilms. We 535 found that the laboratory P. aeruginosa strain PA14 forms a highly structured biofilm on the 536 surface of EVPL tissue. This mature biofilm architecture is comparable to typical P. 537 aeruginosa biofilms that have been observed in explanted lung tissue from people with CF (see 538 Figure 4 in [16] ). The EVPL biofilm appears more 539 structured than has been previously observed in vitro [59], and distinct from the "mushroom" 540 type typically seen in flow cell biofilms (see Figure 8 in [2] ). Our findings support the idea 541 that EVPL mimics a clinically realistic P. aeruginosa biofilm infection. The porcine tissue 542 provides the structure and physiological cues that facilitate the formation of biofilms 543 representative of CF infection. 544
545
To explore the mechanisms responsible for biofilm formation in the EVPL model, we also 546 imaged the biofilm formed by two PA14 transposon mutants: pelA and gacA. We identified 547 clear differences in growth in EVPL. The pelA gene encodes a deacetylase and hydrolase 548 enzyme involved in the synthesis of the biofilm exopolysaccharide pellicle: Pel [52] . Previous 549 studies have shown that the Pel polysaccharide is necessary for cell-cell interactions and 550 development of P. aeruginosa PA14 biofilms [37] . This is consistent with our images showing 551 that the pelA mutant was unable to form a biofilm on the surface of the EVPL bronchiolar 552 tissue. The gacA mutant was found to form a biofilm, however it lacked the structure that was 553 observed for the WT. GacA has been shown to be essential for P. aeruginosa PA14 biofilm 554 maturation, and lack of gacA function results in a reduction in biofilm formation capacity and 555 structure, and reduced antibiotic resistance [36] . Our observations thus confirm the importance 556 of established biofilm regulatory pathways in the formation of the structured communities 557 observed on EVPL tissue. This supports the conclusion that P. aeruginosa is forming a mature 558 biofilm in the EVPL model. 559 560 Further analysis of EVPL infection at a genotypic level will be required to fully conclude which 561 aspects of chronic CF infection dynamics the model is able to recapitulate. However, we 562 present EVPL + ASM1 as a cheap, tractable and high-throughput platform for growing biofilms 563 of P. aeruginosa. The EVPL infections we observed exhibit some of the key morphological 564 and metabolic characteristics observed for this pathogen in CF. Our results clearly demonstrate 565 the importance of visualising biofilms grown in laboratory models. When we compared the 566 CFU per lung of WT, pelA and gacA mutants, there were no clear differences in bacterial 567 recovery -but there were obvious differences in the structure of the biofilms they formed. 568
Visualisation of biofilms formed on EVPL tissue will be a valuable addition to future work, 569 with the aim to understand infection dynamics, antibiotic tolerance, polymicrobial interactions 570 and the ability of novel drugs to penetrate and destroy these biofilms. 571 572 Conclusions 573 574
We have shown, in extension to our previous work [30, 31] , that the EVPL model is able to 575 successfully replicate a phenotypically realistic P. aeruginosa CF lung biofilm. Our work can 576 now be expanded to further understanding of other key aspects of infection, as well as a basis 577 for development of ex vivo models for other biofilm infection contexts. The model provides a 578 high-throughput approach to bridge the gap between in vitro models and true human infection. show relative allocation to biofilm on the plastic pegs, as measured by a crystal violet assay (A592nm of crystal violet bound by each biofilm, divided by the A600nm of the planktonic subpopulation of that well). Each data point is one replica population. ANOVA was used to analyse data and asterisks show conditions for each bacterial strain where growth or biofilm formation was significantly different when contrasted with that in ASM1 without glucose, using a post-hoc Tukey's test. For PA14, planktonic growth was enhanced by addition of glucose (F1,12 = 23.7, p < 0.001) but was not affected by ASM version (main effect F1,12 = 0.73, p = 0.41; interaction with glucose F1,12 = 1.51, p = 0.24). Biofilm allocation by PA14 was higher in ASM2 than ASM1 (F1,12 = 56.0, p < 0.001) and reduced by the presence of glucose (main effect F1,12 = 28.7, p < 0.001; interaction with ASM F1,12 = 4.33, p = 0.059). For SED42, planktonic growth was lower in ASM2 than ASM1 (F1,12 = 33.0, p < 0.01) and enhanced by the addition of glucose (main effect F1,12 = 18.8, p < 0.01; interaction with ASM F1,12 = 4.69, p = 0.51). Biofilm allocation by SED42 was unaffected by either ASM version (F1,12 = 2.05, p = 0.18) or glucose (main effect F1,12 = 0.03, p = 0.86; interaction with ASM F1,12 = 2.06, p = 0.18). For SED43, growth was lower in ASM2 than ASM1 (F1,12 = 14.8, p = 0.002) and unaffected by glucose (main effect F1,12 = 1.17, p = 0.30; interaction with ASM F1,12 = 0.11, p = 0.74).
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Relative Biofilm were infected with each strain. The EVPL tissue was infected for 2 d at 37 °C. Uninfected tissue was used as a negative control. The tissue pieces were washed in PBS and repeatedly stained with 0.1% (v/v) crystal violet.
Following drying of stained tissue, the bound crystal violet was solubilised in 95% (v/v) ethanol and the absorbance read at 590 nm. The highest absorbance measured was for the uninfected tissue sample, indicating that the crystal violet preferentially binds to the tissue over the biofilm. Therefore, this assay was considered unsuitable to measure EVPL-formed biofilms. 
